Wysa's AI front door for mental health: 4.5M users, FDA nod, NHS across 31 services

Wysa is an AI-guided mental-health platform: a freemium chatbot offering CBT-based support, plus a digital 'front door' product that employers and public health systems use for triage, self-referral and waitlist care.

That an empathetic AI can own mental health's front door - triage, CBT self-help and waitlist support - leaving scarce human therapists for the people who need them most.

$9.4M raised before July 2022, then a $20M all-equity Series B led by HealthQuad with British International Investment; a £5.3M Wellcome grant followed in February 2026.

Wysa was conceived in 2016 after co-founder Jo Aggarwal fell into a deep depression and saw how gated professional help was; she and Ramakant Vempati built an AI companion in India offering 'early engagement and a safe space' where people can talk anonymously about what is bothering them.

Wysa grew to 4.5 million users across 65 countries and more than 400 million conversations, with about 80% of revenue from enterprise clients such as Accenture, Colgate-Palmolive, Aetna International and Swiss Re. In May 2022 the FDA granted Breakthrough Device designation, and the UK's NHS and Singapore's Ministry of Health deployed it. By March 2025 it was live across 31 NHS Talking Therapies services, facilitating more than 117,000 self-referrals and supporting over 36,000 people on waitlists, according to Whittington Health NHS Trust.

Wysa is expanding from chatbot vendor into a broader care company - acquiring US physical-therapy provider Kins and psychiatric-care provider April Health, both described as Wysa companies - and in February 2026 Wellcome awarded £5.3 million to adapt its clinically validated intervention for adolescent girls in rural India.

The wedge is the front door, not the therapist: anonymous chat makes people come forward who would never book a session, and built-in crisis detection keeps at-risk users connected to crisis services.

The numbers are attributable: 4.5M users, 65 countries and 400M+ conversations (TechCrunch, 2022); 31 NHS services, 117,000+ self-referrals and 36,000+ waitlist users (Whittington Health, 2025).

Clinical validation differentiates it: FDA Breakthrough Device designation plus NHS and Singapore Ministry of Health deployments signal trust that consumer wellness chatbots lack.

The B2B model gave it a business: roughly 80% of revenue came from enterprise and health-system contracts, not app-store subscriptions.

Put AI where the bottleneck is - the front door of care: automating triage, self-help and waitlist support frees human therapists for severe cases and earns trust through clinical validation.

As of February 2026 Wysa is a digital front door for health systems: 31 NHS Talking Therapies services, 117,000+ self-referrals and 36,000+ waitlist users as of March 2025, plus Singapore's Ministry of Health and employers like Accenture and Swiss Re. It acquired US physical-therapy provider Kins and psychiatric-care provider April Health, both described as Wysa companies, and in February 2026 Wellcome awarded £5.3 million for a rural-India study adapting its intervention for adolescent girls. The open question is whether adoption and clinical evidence convert into durable profitability.